Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Description

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.

Conditions

HIV Infections, Age

Study Overview

Study Details

Study overview

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.

Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Condition
HIV Infections
Intervention / Treatment

-

Contacts and Locations

Minneapolis

Hennepin Healthcare System, Minneapolis, Minnesota, United States, 55415

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age\>=18 years
  • * HIV Diagnosis
  • * On Antiretroviral Therapy with HIV Viral Load\<200 within last year
  • * Other significant immunosuppressing condition
  • * Age\< 18 years
  • * Pregnancy (at enrollment)
  • * Contraindication to pneumococcal vaccination
  • * Known contraindication to non-clinical blood draws (severe anemia last hemoglobin \<8g/dl)
  • * Subjects who, in the opinion of the Investigator, may be non-adherent to study schedules or procedures.
  • * Adults unable to consent
  • * Individuals with impaired ability to consent
  • * Incarceration at time of enrollment

Ages Eligible for Study

18 Years to 95 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Hennepin Healthcare Research Institute,

Study Record Dates

2030-12-14